Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Super-high-yield stocks often deliver heaps of passive income early on, but they aren't famous for rapid payout raises.

Pfizer Inc. closed 26.70% short of its 52-week high of $31.54, which the company achieved on July 30th.

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...

AbbVie is a Dividend King with a strong product lineup. Bristol Myers Squibb offers a high dividend yield and has underrated ...

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

As with any stock, there are very good reasons to consider buying into Pfizer and also some reasons to take a more cautious stance. Here's a look at some reasons why you might buy -- or not buy ...

Dividend stocks are a smart way to navigate an uncertain market. Besides generating steady passive income, dividend-paying ...